Alcedis, a German trial operations firm owned by healthcare AI company Huma, will help turn consumer wrist biometrics into measures of whether a drug actually works. The catch is that regulators still have to qualify that data.
Samsung Electronics has partnered with Alcedis, a Germany-based clinical-trial operations company, to convert Galaxy Watch biometric data into clinical endpoints for drug development. The deal, announced June 24, covers data collection, participant monitoring, trial operations, and regulatory compliance across studies in oncology, cardiology, and neurology. The interesting question is not whether a smartwatch can measure a pulse. It is whether consumer-grade wrist data can survive the regulatory translation from raw signal to a qualified endpoint that the US Food and Drug Administration or the European Medicines Agency will accept as evidence a drug actually worked.
Alcedis is a subsidiary of Huma Group, the London-based healthcare AI company. Samsung is not walking into this cold. It already enrolled the first patient in the HEARTBEAT 10,000 study with Huma and Tulane University, a ten-thousand-participant cardiac risk study that uses Galaxy Watch data. That program gives Samsung prior art in wearable-based endpoint design and an existing relationship with Huma, whose configurable disease-management platform received US FDA 510(k) Class II clearance as Software as a Medical Device.
That regulatory scaffolding matters more than the watch itself. Most consumer-wearable-in-clinical-trial efforts stall not on hardware but on whether regulators will accept the data as primary or secondary efficacy evidence. A 510(k) clearance for a disease-management platform is not the same as endpoint qualification, which is the separate, harder process by which FDA or EMA decides that a specific measurement, say a wearable-derived heart rate variability metric, can support a labeling claim about whether a drug worked. Huma's clearance covers configurable SaMD disease management, per the company's own regulatory materials. It does not by itself qualify any wearable endpoint.
Samsung's bet appears to be that this gap will close. The company has acquired Xealth, a US-based platform that connects hospitals with digital health tools, and plans to pipe Galaxy device data into hospital electronic health record systems. Alcedis, meanwhile, recently expanded its US respiratory contract research organization capabilities through Huma's acquisition of Aluna. The combination gives Samsung not just a sensor partner but a clinical-operations foothold on both sides of the Atlantic.
What is still missing is the part that will determine whether any of this matters to drug developers. The announcement does not name specific trials, sponsors, therapeutic candidates, or timelines. It does not say which Galaxy Watch modalities Samsung and Alcedis plan to promote as endpoints: heart rate, heart rate variability, blood oxygen, electrocardiogram, skin temperature, or bioelectrical impedance each carry a different evidentiary bar. Generic activity counts and step totals are already accepted as supportive secondary measures in some trial designs. Replacing a clinical blood pressure cuff or a treadmill stress test is a different conversation.
The watch item is whether Samsung and Huma file for formal endpoint qualification with FDA or EMA on a specific measurement, and whether the first Alcedis-run Samsung trial uses that endpoint as primary, secondary, or only exploratory evidence. Until then, the partnership is real regulatory infrastructure being laid. The regulatory question it is built to answer remains open.